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Abstract
Context: Multiparametric magnetic resonance imaging (mpMRI) detects most, but
not all, clinically significant prostate cancer. The genetic basis of prostate cancer
visibility and invisibility on mpMRI remains uncertain.
Objective: To systematically review the literature on differential gene expression
between mpMRI-visible and mpMRI-invisible prostate cancer, and to use bioinfor-
matic analysis to identify enriched processes or cellular components in genes
validated in more than one study.
Evidence acquisition: We performed a systematic literature search of the Medline,
EMBASE, PubMed, and Cochrane databases up to January 2020 in accordance with
the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
statement. The primary endpoint was differential genetic features between
mpMRI-visible and mpMRI-invisible tumours. Secondary endpoints were explan-
atory links between gene function and mpMRI conspicuity, and the prognostic
value of differential gene enrichment.
Evidence synthesis: We retrieved 445 articles, of which 32 met the criteria for
inclusion. Thematic synthesis from the included studies showed that mpMRI-
visible cancer tended towards enrichment of molecular features associated with
increased disease aggressivity, including phosphatase and tensin homologue
(PTEN) loss and higher genomic classifier scores, such as Oncotype and Decipher.d s
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further bioinformatic analysis. An over-representation analysis of these datasets
revealed increased expression of genes associated with extracellular matrix
components in mpMRI-visible tumours.
Conclusions: Prostate cancer that is visible on mpMRI is generally enriched with
molecular features of tumour development and aggressivity, including activa-
tion of proliferative signalling, DNA damage, and inflammatory processes.
Additionally, there appears to be concordant cellular components and biological
processes associated with mpMRI conspicuity, as highlighted by bioinformatic
analysis of large genetic datasets.
Patient summary: Prostate cancer that is detected by magnetic resonance
imaging (MRI) tends to have genetic features that are associated with more
aggressive disease. This suggests that MRI can be used to assess the likelihood of
aggressive prostate cancer, based on tumour visibility.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).
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Multiparametric magnetic resonance imaging (mpMRI) has
enhanced risk stratification for men at a risk of prostate
cancer, through accurate prebiopsy detection of clinically
significant disease [1]. However, approximately 10–20% of
clinically significant prostate cancers are not detected by
mpMRI [1], and the nature of mpMRI-invisible disease
remains a potential source of concern.
The biology underlying mpMRI conspicuity of prostate
cancer is poorly understood; however, tumour visibility on
mpMRI appears to be associated with disease significance
and aggressivity [2]. Disease aggressivity in prostate cancer
can be defined clinically in several ways, including reduced
time to recurrence following treatment, time to metastasis,
and prostate cancer–specific mortality. Pathologically, the
Gleason grading system appears to correlate with clinical
outcome, with higher-grade disease exhibiting increased
features of disease aggressivity [3]. Furthermore, aggressive
cancer is known to harbour particular genomic hallmarks,
including MYC amplification, ATM mutation, hypermethyla-
tion of TCERG1L (50 upstream), and loss of PTEN [4]. The
potential mechanistic association of these molecular
features with mpMRI phenotypes and their prognostic
significance has been an area of recent research focus [5],
now warranting collation.
Here, we systematically review the evidence surround-
ing the genomic characteristics underlying the mpMRI
conspicuity of prostate cancer, for the first time. We also
identify genes associated with mpMRI conspicuity, which
are experimentally validated, and identify enriched path-
ways and functions using publicly available mpMRI-
correlated genetic databases.
2. Evidence acquisition
2.1. Study design
The protocol for this systematic review and bioinformatic
analysis has been published in detail elsewhere [6], and wasbased on the Preferred Reporting Items for Systematic
Review and Meta-analysis Protocols (PRISMA-P) statement.
This review was also prospectively registered in the
PROSPERO International Registry (CRD42019147423).
2.2. Literature search
A systematic search of the literature was conducted from
1990 to 2020 in four databases: MEDLINE, PubMed,
EMBASE, and Cochrane. Controlled vocabulary was selected
in the search engines to reduce the number of unrelated
studies. The search strategy contained 11 components
linked by the AND/OR operator terms: (Prostate AND
cancer) AND (gene OR genetic OR genome OR genomic OR
transcriptome OR transcriptomic OR epigenetic) AND
(magnetic resonance imaging OR MRI).
2.3. Study selection
Figure 1 shows an overview of the evidence acquisition
process. Two investigators (B.S.S. and J.M.N.) independently
screened eligible studies, assessing titles and abstracts for
relevance. Full texts were retrieved and reviewed further for
eligibility. Lack of concordance between reviewers was
discussed until consensus was reached or passed to a third
reviewer (M.A.P.). For inclusion in the analysis, studies had
to demonstrate investigation of the genomic aspects of
localised prostate cancer conspicuity on mpMRI. Genomic
investigation was at the DNA level, including larger-scale
alterations (copy-number changes or methylation). Tran-
scriptomic data analysing RNA expression (coding or
noncoding) or microRNA were also included. All proteomic
methodologies were accepted, including immunohis-
tochemistry (IHC). Conference abstracts, correspondence
articles, expert opinions, and case reports were excluded.
Studies that did not correlate tumour visibility on mpMRI
with genomic data were excluded. Articles focusing solely
on clinical or histopathological features of mpMRI conspi-
cuity were removed. Studies that focused on advanced or
metastatic prostate cancer were excluded.
Fig. 1 – PRISMA flow diagram of evidence acquisition. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses.
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Identified articles were uploaded to Rayyan (a web and
mobile application for systematic reviews) to expedite
initial screening and allow reviewers to filter studies.
Reference sections of included articles were searched
manually to identify missed studies and additional data.
All extracted data were collected by two investigators (B.S.S.
and J.M.N.) using a standardised form. Both reviewers
extracted data independently and agreed by consensus.
2.5. Quality assessment
Risk of bias assessment was conducted using a modified
Newcastle-Ottawa scale. Studies were assessed on grounds
of patient selection, comparability, and outcome. Large
biopsy cohorts were considered most representative,
encompassing an accurate cross section of disease upon
diagnosis, followed by smaller biopsy cohorts (<50
patients) and then radical prostatectomy cohorts, and
finally nonrepresentative sampling from another route.
The Newcastle-Ottawa scale is intended for traditional
clinical outcome–focused meta-analyses, so we simplified
outcome measures to a single parameter whereby the
quality of genetic outcome was assessed. Unbiased whole
genome, methylome, transcriptome, or proteome-based
approaches were considered gold standard (two stars),
followed by large-scale but limited methods based on
arrays or very large gene panels (one star) and then
selected gene panels (such as those used in commercial
assays), and lastly, approaches that investigated single
genes. The Newcastle-Ottawa scale allowed for a maxi-
mum of eight stars: four for selection, two for compara-
bility, and two for outcome.2.6. Data synthesis
The primary endpoint was differential gene expression
between mpMRI-visible and mpMRI-invisible tumours.
Secondary endpoints were explanatory links between gene
function and mpMRI conspicuity, and potential prognostic
value of differential gene enrichment. Key themes were
derived from the included the literature with a focus on
mpMRI scoring systems used (eg, Prostate Imaging Report-
ing and Data System [PI-RADS], Likert, and radiogenomic
features), criteria used to define tumour visibility (usually a
PI-RADS or Likert score cut-off), and the type of cohort used
in the study (eg, radical prostatectomy or biopsy cohort).
2.7. Bioinformatic analysis
In the identified articles, there were an insufficient number
of studies with single endpoints and comparable method-
ologies to conduct a typical meta-analysis. Therefore, an
additional search was conducted to identify available
genetic datasets for bioinformatic analysis in the NCBI
GEO and European genome-phenome archives. For re-
trieved transcriptomic data, Log2-fold changes and associ-
ated false discovery rate (FDR)-adjusted values were
compared between mpMRI-visible and mpMRI-invisible
tumours. Differential gene expression was compared
between studies; if unavailable, highlighted genomic
features and the direction of change (eg, correlation
coefficient) were compared between groups. Genes
highlighted in multiple studies were used (via over-
representation analysis) to identify enriched pathways,
components, and functions. Analyses were performed using
the WebGestalt, a gene set analysis toolkit. This method
enables a standardised and robust analysis, as it does not
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effect size differed between studies) and uses a modified
Fisher’s exact test to identify enriched biological processes.
3. Evidence synthesis
3.1. Study characteristics
We retrieved 445 articles: 262 from EMBASE, 129 from
Medline, 42 from Cochrane, eight from PubMed, and four
from reference searching or expert suggestion. Of these,
32 articles were eligible for further analysis (Table 1). Of
the 32 studies, 14 used prostate biopsy as the source of
prostate tissue for genetic analysis, 16 used radical
prostatectomy specimens, and two used a combination
of these two approaches. Median study size was 51 (range
2–532). The PI-RADS reporting scheme was the most
commonly used mpMRI reporting approach, with 21 of the
included studies using this system or a modified version.
Of those using PI-RADS, 14 used PI-RADSv2. Assessment by
an expert radiologist was the second most common
mpMRI scoring approach, employed in six studies,
followed by scores based on radiomic-derived features,
used in three of the studies. Two studies used a modified or
different reporting measure. For the purpose of compari-
son, 12 studies chose to discretise scoring systems into
“mpMRI-visible” and “mpMRI-invisible” tumours, with the
exception of two studies that included an “indeterminate”
category. Definitions of tumour conspicuity on mpMRI
were heterogeneous between studies, with one study
defining visibility (or high clinical suspicion) as PI-RADS
scores 2–5, five as PI-RADS scores 3–5, three as PI-RADS
scores 4–5, and two as PI-RADS score 5. Regarding magnet
strength, 3 Tesla systems were most common, used in 21/
32 studies, with 5/32 using 1.5 Tesla systems (two studies
used both magnet strengths). Four did not report the
magnet strength, and 24 did not report echo times. The
majority of studies (26/32) assessed mRNA to derive
transcriptomic data in relation to mpMRI signal and used
most commonly microarray or RNAseq methods (18 stud-
ies). Protein-based studies were the second most common
approach (8/32) with all studies using IHC, followed by
studies using DNA sequencing (seven studies). Two studies
looked at DNA methylation. In studies using mRNA, 22 used
samples processed with formalin-fixed paraffin embed-
ding, three used fresh frozen tissue, and six used fluid
biomarkers. One study did not state the preparation
method. Seven studies used macrodissection prior to
genomic analysis, two used microdissection, and eight
used neither (often, tissue punches), and in 15 studies, this
was not applicable given the study methodology.
3.2. Thematic synthesis
3.2.1. Association of mpMRI conspicuity and clinically validated
genetic biomarker panels
Validated commercial assays for the detection of prostate
cancer or assessment of aggressive disease were investi-
gated in 16 studies. Additionally, several larger-scaleinvestigations used panels derived from these assays as
part of their analysis.
Progensa prostate cancer antigen 3 (PCA3) is a prognostic
marker that measures the ratio of PCA3 to PSA (KLK3) mRNA
and was found to be significantly higher in patients with
mpMRI-visible tumours [7,8]. In contrast, another study
found no correlation between PCA3 level and tumour
conspicuity; however, this study had a relatively small
sample size (n = 49) [9]. Two other studies supported the
use of PCA3 in conjunction with mpMRI to improve
diagnostic accuracy significantly; however, they did not
compare mpMRI-visible and mpMRI-invisible cancers
[10,11], and this was also true of the STKHLM3 assay [12].
Oncotype Dx genomic prostate score (GPS) is another
prognostic marker, based on an RNA expression assay of
17 genes that is associated with pathological stage, grade,
disease recurrence, and prostate cancer–specific mortality.
Leapman and colleagues [13] found a significant association
between GPS and prostate cancer visibility on mpMRI
[13]. This association persisted only for men with significant
disease (defined as Gleason score  3 + 4 cancer) [13]. These
findings were reiterated in other studies describing an
association between GPS and mpMRI visibility of clinically
significant prostate cancer [14,15].
Decipher, a genomic classifier (GC), is a 22-gene
prognostic signature associated with early metastasis of
prostate cancer [16]. Overall, mpMRI-visible tumours
appear to have increased Decipher scores compared with
mpMRI-invisible tumours, in both biopsy cohorts and
radical prostatectomy cohorts [17–20]. In contrast, two
recent studies found no major association of a GC-based
gene signature and tumour conspicuity on mpMRI;
however, this may be attributed to a small sample size
(n = 6) [21] and a low- to intermediate-risk cohort,
mirroring similar results to studies using Oncotype DX in
this patient population [13,15,22]. Additionally, another
study found that GC added significant value to mpMRI in
predicting adverse pathology upon radical prostatectomy,
but did not correlate GC with mpMRI features directly
[18]. In terms of radiogenomics, GC score was found to be
most highly correlated with grey-level co-occurrence
matrix (GLCM) texture, a measure of regularity and local
spatial variation of intensity or colour brightness in an
image to determine its texture [13,23]. Thus, GC-related
genes tend to correlate with mpMRI features, but, as with
other candidate genes, only correlative studies have been
performed without controlling for additional pathological
factors that exist between mpMRI-visible and mpMRI-
invisible tumours.
Finally, Prolaris cell cycle progression (CCP) is a
prognostic gene signature comprising CCP-associated genes
wherein each 1-unit increase in CCP score represents
doubling of the risk of prostate cancer–specific mortality.
PI-RADS was weakly correlated with CCP (r = 0.26,
p = 0.007), but was able to predict a CCP score of >0 with
sensitivity and specificity of 80.0% and 40.9%, respectively
[24]. However, a small number of tumours with high
CCP were overlooked by mpMRI [24]. Conversely, Wibmer
et al [25] compared the CCP gene signature between
Table 1 – Descriptive characteristics of included studies
Author Year Ref. Cohort n Matched
cohort
mpMRI
scoring
system
Visible
definition
Invisible
definition
Intermed.
definition
DNA DNA
methylation
RNA Protein Genes Platform Preparation Dissection Tesla Echo
time (ms)
Lenkinski 2008 [46] Radical 2 No Suspicious/
nonsusp
– – – No No Yes Yes Multiple Microarray/IHC Fresh/frozen Macro 3.0 165
Leyten 2013 [7] Biopsy 115 No Suspicious/
nonsusp
– – – No No Yes No PCA3 Commercial test FFPE – 3.0 –
Busetto 2013 [10] Biopsy 171 No Suspicious/
nonsusp
– – – No No Yes No PCA3 PCA3 assay – – 3.0 –
Renard-Penna 2015 [24] Radical 106 No PI-RADSv1 – – – No No Yes No CCP RT-PCR FFPE Macro 3.0 7–12
Kaufmann 2016 [9] Biopsy 49 No PI-RADSv1 sum
score
7 <7 – No No Yes No PCA3 PCA3 assay – 1.5 –
Stoyanova 2016 [29] Biopsy 6 No Radiomic features – – – No No Yes No Multiple Microarray FFPE Macro 3.0 2.8–83
McCann 2016 [44] Radical 30 No Radiomic features – – – No No No Yes PTEN IHC FFPE – 3.0 –
De Luca 2016 [8] Biopsy 282 No PI-RADSv1 – – 3 No No Yes No PCA3 PCA3 assay – 1.5 –
Dulaney 2017 [27] Biopsy 11 No PI-RADSv2 5 1–4 – No No Yes No Multiple Microarray FFPE Micro – –
Lee 2017 [45] Radical 48 No PI-RADSv2 2–5 1 – Yes No No Yes Multiple FISH/sanger/IHC FFPE – 1.5/3.0 1.3–105.6
Leapman 2017 [13] Biopsy 100 No PI-RADSv1
(modified)
4–5 1–2 3 No No Yes No Oncotype RT-PCR FFPE None 3.0 –
Jamshidi 2017 [35] Radical 6 No Suspicious/
nonsusp
– – – Yes No No No Multiple Whole exome FFPE Macro 3.0 1.4–120
Palapattu 2017 [47] Biopsy 31 No Suspicious/
nonsusp
– – – Yes No Yes Yes Multiple DNA/RNAseq/IHC FFPE – 3.0 –
Fenstermaker 2017 [11] Biopsy 187 Yes mSS – – – No No Yes No PCA3 PCA3 assay – – 3.0 –
Gronberg 2018 [12] Biopsy 532 No PI-RADSv2 3–5 2–1 – No No No Yes STHLM3 Protein assay – – 1.5 –
Radtke 2018 [20] Combo 11 No PI-RADSv2 4–5 1–2 – No No Yes No Multiple Microarray FFPE Macro 3.0 –
Li 2018 [26] Radical 16 No PI-RADSv2 4–5 1 – No No Yes Yes Multiple RNAseq FFPE Macro 3.0 11–125
Kesch 2018 [32] Biopsy 5 No PI-RADSv1 – – – Yes Yes No No Multiple Methylation array Not stated – 3.0 –
Salmasi 2018 [14] Combo 134 No PI-RADSv2 – – – No No Yes No Oncotype Microarray FFPE – 3.0 –
Beksac 2018 [17] Radical 206 No PI-RADSv1 – – – No No Yes No Multiple Microarray FFPE None 3.0 –
Houlahan 2019 [2] Radical 40 Yes PI-RADSv2 5 1–2 – Yes No Yes No Multiple CNA/SNParray/
RNAseq
FFPE Macro – –
Parry 2019 [21] Radical 6 No PI-RADSv2 3–5 1–2 – Yes Yes Yes No Multiple Multiple Fresh/
frozen
None 1.5 64–107
Baumgartner 2019 [37] Biopsy 53 Yes PI-RADSv2 3–5 1–2 – No No No Yes PTEN/ERG IHC FFPE – – –
Purysko 2019 [19] Radical 72 No PI-RADSv2 3–5 1–2 – No No Yes No Decipher Microarray FFPE Micro 3.0 –
Hectors 2019 [30] Radical 64 No PI-RADSv1 – – – No No Yes No Multiple Microarray FFPE None 3.0 –
Martin 2019 [18] Biopsy 102 Yes PI-RADSv2 – – – No No Yes No Decipher Microarray FFPE – 3.0 –
Wibmer 2019 [25] Biopsy 118 No PI-RADSv2 – – – No No Yes No CCP Microarray FFPE – 3.0 7–120
Kornberg 2019 [15] Biopsy 131 No PI-RADSv2 – – – No No Yes No Oncotype Microarray FFPE – 3.0 –
Falagario 2019 [22] Radical 520 No Suspicious/
nonsusp
– – – No No Yes No Decipher Microarray – None 1.5/3.0 –
Switlyk 2019 [43] Combo 43 No ADC – – – No No Yes No PTEN Bead array,
RT-PCR
Fresh/
frozen
None 1.5 –
Sun 2019 [34] Radical 6 No Radiomic features – – – No No Yes Yes Multiple RNAseq FFPE None 3.0 –
Salami 2019 [36] Radical 10 No PI-RADSv2 3–5 1–2 – Yes No Yes No Multiple Multiple FFPE None – –
ADC = apparent diffusion coefficient; CCP = cell cycle progression (Prolaris) score; CNA = circulating nucleic acid; Intermed. = intermediate/indeterminate score; ERG = ETS-related gene; FFPE = formalin-fixed paraffin
embedded; FISH = fluorescence in situ hybridisation; IHC = immunohistochemistry; mpMRI = multiparametric magnetic resonance imaging; N = number of patients; PCA3 = prostate cancer antigen 3; PI-RADS = Prostate
Imaging Reporting and Data System; PTEN = phosphatase and tensin homologue; Ref. = reference; RNAseq = RNA sequencing; RT-PCR = real-time polymerase chain reaction; SNParray = single nucleotide polymorphism
array; STHLM3 = Stockholm3 test; susp. = suspicious.
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significant difference [25]. Significant differences in CCP
scores were, however, observed between patients with and
without extracapsular disease extension on mpMRI [25].
3.2.2. Association of mpMRI conspicuity with biological pathways
and functions
Transcriptomic analysis was used in 18 studies to identify
key pathways differing between mpMRI-visible and
mpMRI-invisible tumours. Several studies used gene set
enrichment analysis or over-representation analysis to
identify enriched processes, pathways, or functions.
Pathways that regulate cell cycle and growth appear to
be related to mpMRI conspicuity. Li and colleagues [26]
reported enriched processes of mitotic cell cycle, protein
folding, cell cycle, mitotic cell cycle process, and cell division
in mpMRI-visible cancers. Furthermore, Dulaney and
colleagues [27] reported that tumours with a PI-RADS
score of 5 had significantly more deregulation of pathways
involved in apoptosis and cell cycle (in particular, TGFb,
STAT, and RAS pathways) compared with mpMRI-invisible
tumours; however, this was unadjusted for multiple testing
and this study scored relatively low using the modified
Newcastle-Ottawa scale (3/8), indicating a potential a risk of
bias. Finally, Beksac et al [17] reported that pathways
associated with CCP (PI3K-AKT-mTOR and E2F) and castra-
tion resistance (WNT-b) were found to be more active in
mpMRI-visible cancer (PI-RADSv2 score of 5) than in
mpMRI-invisible cancer.
Another major hallmark of aggressive cancer is evasion
of immune destruction, and this was highlighted across
several articles [28]. Stoyanova et al [29] reported increased
immune/inflammatory and cell-stress responses in mpMRI-
visible tumours in both the peripheral zone and the
transitional zone, as derived through radiomic feature
analysis. Another radiogenomic study reported significant
enrichment of genes involved in immune responses in
mpMRI-visible tumours, as defined by ADC GLCM energy-
derived features [30]. As further indicative evidence of the
immunological component of mpMRI conspicuity, Houla-
han et al [2] reported a 200-fold increase in ANKRD30A (NY-
BR-1; a tumour-specific antigen that selectively activates
CD8 + T cells) in mpMRI-visible cancers.
DNA damage repair pathway defects play an important
role in prostate cancer carcinogenesis and progression, and
mutations are present in around 19% of prostate tumours of
Gleason grade  8 [31]; these also appear to play a role in
tumour conspicuity on mpMRI. Dulaney et al [27] noted
significantly higher deregulation of DNA repair–related
genes in mpMRI-visible targeted tumours with higher
dynamic contrast enhancement values, as also noted in
other studies [26]. Another case study found lower ADC
values in tumour regions with a greater number of copy-
number alterations and higher mutational burden
[32]. Houlahan et al [2] also quantified genomic instability
using the percentage of the genome altered (PGA) via copy-
number alterations, finding elevated PGA in visible tumours
(p = 0.03) with increased average length of individual
amplifications and deletions. Tumour hypoxia is believedto be a characteristic driving cancer instability [33] and has
been shown to correlate with mpMRI-derived radiomic
features [34]. Contrasting this, a different study found no
significant difference in mutation load in cancer-associated
genes between regions that were histopathologically
benign and had low clinical suspicion on mpMRI, interme-
diate clinical suspicion on mpMRI, and high-grade cancer
histopathologically; however, this study was limited by its
small sample size (n = 6) [35].
Lastly, gene sets involved in cell structure (eg, actin
filament-based process and cytoskeleton organisation)
were downregulated in mpMRI-invisible tumours, which
may explain the physical properties (such as lower tissue
density) associated with mpMRI-invisible cancer [26]. Sala-
mi et al [36] also identified an MRI-visibility signature
comprising predominantly cell organisation/structure
genes from 10 patients, which was able to distinguish
MRI-visible tumours in an independent cohort with an area
under the curve (AUC) of 0.88. This is further supported by
the association of stromal-associated genes in the Oncotype
DX assay being significantly associated with PI-RADS score,
with little association seen in other gene groups [13].
3.2.3. Association of mpMRI conspicuity with genetic markers for
cancer aggressivity and prognosis
The association of PTEN loss (a known driver of prostate
cancer) and mpMRI conspicuity was assessed in three
included studies. PTEN loss was shown to be higher in
mpMRI-targeted biopsies (ie, of mpMRI-visible tumours)
than in non–image-guided systematic biopsies (ie, not of
mpMRI-visible tumours) [37]. This result is concordant with
the fact that PTEN loss is highly correlated with Gleason
grade and stage [38–40] and that mpMRI-targeted biopsies
detect more clinically significant tumours compared with
systematic biopsies [1,41,42]. However, even when Gleason
grade was controlled for, PTEN loss remained higher in the
targeted biopsy group. A similar association between PTEN
loss and ADC values was demonstrated in a radical
prostatectomy population; however, no correlation be-
tween PTEN expression and Gleason grade was shown
[43]. Other studies found an association with Gleason score
(r =  0.30, p = 0.04) and Kep (r =  0.35, p = 0.02) but not
with ADC [44]. In contrast, a separate radical prostatectomy
study found no association between PTEN and mpMRI
characteristics; however, this study included PI-RADS score
2 tumours as visible, which may skew the study findings
[45].
Li et al [26] performed a full-scale transcriptomic
analysis of mpMRI-visible tumours compared with
mpMRI-invisible tumours [26]. They found 1654 differen-
tially expressed genes between these two visibility pheno-
types. Expression of CENPF, AGR2, and GDF15 was found to
be enriched in mpMRI-visible tumours and was associated
with reduced time to biochemical recurrence in an
independent dataset, suggesting a potential link between
mpMRI visibility and prognostic outcome [26]. CENPF (part
of the Prolaris panel) was also suppressed using an
inducible miRNA system in vivo, showing a reduction in
mpMRI visibility when expression was reduced, suggesting
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and mpMRI conspicuity of prostate cancer [26]. Transcrip-
tomic analysis also identified genes associated with tumour
aggression in mpMRI-visible tumours, such as noncoding
RNA SCHLAP1 (linked to prostate cancer progression),
several small nuclear RNAs [2], and angiogenesis factor
VEGF [46]. Indeed, mutations in tumorigenic drivers such as
SPOP and IDH1 have been found even in lower-grade
mpMRI-visible tumours [47].
One study derived an mRNA signature that could
accurately predict visibility in both a training and a
validation cohort (AUC = 0.89 and 0.88, respectively) but,
when applied to The Cancer Genome Atlas cohort, found no
significant differences in biochemical recurrence, distant
metastasis, or cancer-specific mortality. However, this
signature was derived and tested on a total of 26 patients,
and the mpMRI visibility groups that were predicted did not
significantly differ by Gleason grade, positive lymph nodes,
or positive surgical margins, which somewhat contradicts
other histopathological evidence [36,48].
3.3. Bioinformatic synthesis
We identified four studies with available data for bioinfor-
matic analysis, three of which were large enough to compare
the performance of gene panels [2,26,29]. All three studiesFig. 2 – Bioinformatic synthesis of included studies. (A) Venn diagram of genet
diagrams for each study (studies by Houlahan et al [2], Li et al [26], and Stoyan
significant differentially expressed genes identified in each study and over-rep
genes. mpMRI = multiparametric magnetic resonance imaging.used macrodissection of tumour tissue prior to nucleic acid
extraction. For each study, we included a nonoverlapping list
of significantly altered or significantly correlated genes. For
example, in one study [29], a selection of genes were
correlated with multiple radiological features; in this case,
every gene that was significantly correlated with at least one
radiological feature was included in our analysis (196 total).
We identified 42 genes that demonstrated differential
expression between mpMRI-visible and mpMRI-invisible
tumours (in two or more of the included studies; Fig. 2A). Of
note were GDF15 and AGR2, which are purportedly involved
in tumour progression [49–52]. Interestingly, 14 of the
identified MRI conspicuity–related genes were reported in
studies that used a matched cohort methodology, suggesting
that the influence of these genes may be independent of
Gleason grade. Shared cellular components were over-
represented in two studies [26,29], namely, anchoring
junction (p < 1.00E15 and p = 0.0051), adherens junction
(p = 1.34E12 and p = 0.0041), focal adhesion (p = 1.34E12
and p = 0.0041), cell-substrate adherens junction (-
p = 1.57E12 and p = 0.0041), and cell-substrate junction
(p = 2.11E-12 and p = 0.0041; Fig. 2). These cellular compo-
nents are all involved in anchoring of cells to the
extracellular matrix (ECM) or other cells, primarily through
actin filaments or other components of the cytoskeleton. We
found no significant over-representation of any componentsic overlap for mpMRI conspicuity–associated genes and (B–D) chord
ova et al [29], respectively) illustrating over-representation analysis of
resented cellular component gene ontology terms associated with these
Table 2 – Summary of genetic features associated with tumour visibility on mpMRI
Feature type Feature Reference
Commercial assays Progensa PCA3 [7,8]
Oncotype Dx [13–15]
Decipher (GC) [17–20]
Prolaris (CCP) [24]
DNA-related features DNA repair defects [26,27]
Copy-number alteration [32]
Mutational burden [32]
Genomic instability (PGA) [2]
PTEN loss [37,43,44]
Transcriptomic features Biochemical recurrence–associated genes (CENPF, AGR2, GDF15) [26]
Cancer progression–associated genes (SCHLAP1) [2]
Small nuclear RNAs [2]
Angiogenesis factor (VEGF) [46]
Tumorigenic drivers (SPOP, IDH1) [47]
Biological hallmarks of cancer Castration resistance (WNT) [27]
Immunological response [2,28,29]
Tumour hypoxia [34]
Tumour progression (GDF15, AGR2) [2,26,29]
Biological pathways Mitotic cell cycle [26]
Protein folding [26]
Cell cycle [26,27]
Mitotic cell cycle process [26]
Cell division [26]
Apoptosis [27]
Cell cycle progression (PI3K-AKT-mTOR and E2F) [27]
Cellular structure components Actin filament-based process [26]
Cytoskeleton organisation [26,36]
Stromal components [13]
Anchoring junction [26,29]
Adherens junction [26,29]
Focal adhesion [26,29]
Cell-substrate adherens junction [26,29]
Cell-substrate junction [26,29]
Actin-based cell projection [26,29]
AGR2 = anterior gradient 2, a protein disulphide isomerase family member; AKT = AKT serine/threonine kinase; CENPF = centromere protein F; CCP = cell-cycle
progression; E2F = E2F transcription factor; GC = genomic classifier; GDF15 = growth differentiation factor 15; IDH1 = isocitrate dehydrogenase (NADP + ) 1;
mpMRI = multiparametric magnetic resonance imaging; mTOR = mechanistic target of rapamycin kinase; PCA3 = prostate cancer antigen 3; PGA = percentage of
genome altered; PI3K = phosphoinositide 3-kinase, PTEN = phosphatase and tensin homologue; SCHLAP1 = SWI/SNF complex antagonist associated with
prostate cancer 1; SPOP = speckle type BTB/POZ protein; VEGF = vascular endothelial growth factor; WNT = Wnt signalling pathway.
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closest enriched component was actin-based cell pro-
jection (raw p = 0.0027, after FDR p = 0.67), further
implicating cell-ECM interaction as a determinant of
conspicuity.
From the derived themes, several panels of genes were
suggested to be altered between mpMRI-visible and
mpMRI-invisible tumours. In order to compare how
matching for size and grade may alter this result, we
assessed the Log2-fold change of each gene within the
panels and RNAseq data from two studies: one that
matched for Gleason grade and tumour volume [2], and
one that did not match for these factors [26]. Overall, gene
signatures had more significantly altered genes between
mpMRI-visible and mpMRI-invisible tumours in the un-
matched study [26] compared with the matched study [2],
which suggests that their discriminant ability may derive
from the association with Gleason grade and tumour size,
rather than purely conspicuity. The effect sizes seen in
unmatched study [26] also tended to be of greater
magnitude.3.4. Risk of bias
Overall, all included studies scored highly in the Newcastle-
Ottawa scale, indicating an acceptably low risk of bias, with
24 studies scoring above five stars out of eight (Supple-
mentary Fig. 1). All studies scored highly on patient
selection; however, a potential bias was the prevalence of
studies based on radical prostatectomy specimens, which
reduced generalisability of findings. The second major risk
of bias identified was the use of smaller-scale genetic
investigations, with 17 studies using either small targeted
panels or single gene investigations. Some of the included
studies scored low (or zero) on outcome due to single-gene
investigation methodology.
3.5. Discussion
Here, we have provided a large contemporary systematic
review and bioinformatic analysis of the molecular evi-
dence of prostate cancer conspicuity on mpMRI (Table 2).
Visible mpMRI tumours are generally associated with
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creased Decipher and Oncotype scores, and greater
frequency of PTEN loss. This association is strengthened
by increased enrichment of pro-proliferative signalling
pathways, increased genome instability, DNA damage repair
defects, and hypoxia in mpMRI-visible tumours. On balance,
we found no overall, or comparable, genetic evidence of
increased aggression in mpMRI-invisible tumours com-
pared with that in mpMRI-visible tumours; however, there
were infrequent, isolated reports of mpMRI-invisible
prostate cancer bearing genomic hallmarks of aggressivity,
which warrants future investigation.
Transcriptomic data suggest that there is likely no single
underlying biological process or pathway driving mpMRI
visibility. However, cell-cell– and cell-ECM–associated
genes exhibit differential expression between mpMRI-
visible and mpMRI-invisible tumours, suggesting a possible
explanation for the histopathological characteristics of
prostate cancer conspicuity on mpMRI (including, cellular
density).
Future research effort should focus on exploring the
molecular basis of tumour visibility in larger patient
cohorts. Indeed, the Re-IMAGINE trial (NCT04063566) will
investigate the role of genetic biomarkers in conjunction
with mpMRI for the diagnosis of prostate cancer and will
provide important answers in this field. Furthermore, the
current literature is skewed towards transcriptomic analy-
sis, and may benefit from further DNA and epigenetic
investigation.
Lastly, the studies included in this review used numeric
radiological scoring systems (predominantly, Likert and PI-
RADS) to define “visibility” and “invisibility”, and then
compared genetic features between these two groups. As
discussed, this methodology is fruitful to inform which
features have higher enrichment in mpMRI-visible tumours
than in mpMRI-invisible tumours. However, this approach
does not necessarily provide a detailed description of the
unique genetic features of what mpMRI-invisible disease
may harbour, and dedicated research focussed primarily on
disease invisibility is still warranted in the future. We also
noted that many studies did not include detailed method-
ology around mpMRI scan acquisition, which could
potentially affect the results; therefore, future studies
may benefit from improved transparency to increase
replicability.
It is increasingly apparent that tumour grade and size are
not the only important histopathological determinants of
tumour visibility and invisibility, with evidence that
patterns such as intraductal carcinoma and cribriform
pattern may have reduced visibility on mpMRI [53]. Unfor-
tunately, a very small minority of the included studies in
this review (4/32) used a matched cohort methodology,
meaning that, in the majority of studies (28/32), the genetic
influences on tumour conspicuity cannot be separated from
the important influence that both tumour grade and volume
have. Future studies would benefit from more rigorous
histopathological matching [54] to help reveal the genetic
aspects of disease conspicuity, beyond those associated
with increased Gleason grade and tumour volume. Howev-er, this increases the difficulty in obtaining large sample
numbers, particularly with continuous features such as
tumour volume. Alternatively, following the advent of
spatial transcriptomics, future research could use an
internal matched control methodology, to potentially
illuminate distinct genetic signatures in visible and invisible
regions of the same prostate.
Lastly, mpMRI-visible tumours are more likely to have
genetic variations that drive proliferation and therapeutic
resistance. Therefore, if validated, mpMRI may have clinical
utility in risk stratification and treatment selection, as
tumour conspicuity may confer useful additional informa-
tion, beyond tumour grade and size [4,34]. Additionally,
almost all current studies are correlative, and we found only
a single instance whereby visibility-associated genes were
verified in a model; as such, there is still extensive scope for
future work to establish causative links [26].
4. Conclusions
Prostate cancer that is visible on mpMRI is generally
enriched with molecular features of disease aggressivity
and tumour development, including activation of prolifer-
ative signalling, DNA damage, and inflammatory processes.
Bioinformatic analysis demonstrates concordant cellular
components and biological processes associated with
mpMRI conspicuity, which may in part account for the
histopathological features of MRI-visible prostate cancer,
such as higher Gleason grade disease and increased cellular
density. Future radiobiological studies in this field should
endeavour to use matched cohort-based methodology to
elucidate genetic aspects of tumour conspicuity more
clearly, when tumour size and grade are accounted for.
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